IGF1R and breast neoplasm: IGF-1R expression was significantly lower in the recurrent lesions, compared to the primary tumors.[14] These results show that endocrine therapy can downregulate IGF-1R expression and, therefore, this result argues against combining endocrine therapy with IGF-1R inhibitors, or treating hormone therapy resistant breast tumors with anti-IGF-1R antibodies.